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Abstract 
Objectives: Neurotrophin-3 (NT3) plays a key role in the development and function of locomotor 
circuits including descending serotonergic and corticospinal tract (CST) axons and afferents from 
muscle and skin. We have previously shown that gene therapy delivery of human NT3 into 
affected forelimb muscles improves sensorimotor recovery after stroke in adult and elderly rats. 
Here, to move towards the clinic, we tested the hypothesis that intramuscular infusion of NT3 
protein could improve sensorimotor recovery after stroke. 
Methods: Rats received unilateral ischemic stroke in sensorimotor cortex. To simulate a clinically-
feasible time-to-treat, twenty-four hours later rats were randomized to receive NT3 or vehicle by 
infusion into affected triceps brachii for four weeks using implanted catheters and minipumps. 
Results: Radiolabelled NT3 crossed from the bloodstream into the brain and spinal cord in 
rodents with or without strokes. NT3 increased the accuracy of forelimb placement during walking 
on a horizontal ladder and increased use of the affected arm for lateral support during rearing. 
NT3 also reversed sensory impairment of the affected wrist. fMRI during stimulation of the 
affected wrist showed spontaneous recovery of peri-infarct BOLD signal that NT3 did not further 
enhance. Rather, NT3 induced neuroplasticity of the spared corticospinal and serotonergic 
pathways.  
Interpretation: Our results show that delayed, peripheral infusion of NT3 can improve 
sensorimotor function after ischemic stroke. Phase I and II clinical trials of NT3 (for constipation 
and neuropathy) have shown that peripheral, high doses are safe and well tolerated, which paves 
the way for NT3 as a therapy for stroke. 
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Introduction 
Ischemic stroke occurs in the brain when blood flow is restricted, causing brain cells to die rapidly. 
Worldwide, there are an estimated 31 million stroke survivors, with another 9 million new strokes 
annually. Therapies that reverse impairments are urgently needed1. 
Neurotrophin-3 is a growth factor which plays a key role in the development and function of 
locomotor circuits including descending serotonergic2 and corticospinal tract (CST) axons3 and 
afferents from muscle and skin that mediate proprioception and tactile sensation4-6. However, 
levels of NT3 drop in the postnatal period7. We and others have shown that delivery of NT3 into 
the CNS promotes recovery in models of spinal cord injury8-15 but this involved invasive routes of 
delivery or gene therapy. We also recently showed that injection of an adeno-associated viral 
vector (AAV) encoding full-length human NT3 (preproNT3, 30kDa) into forelimb muscles 24 hours 
after stroke in adult or elderly rats in adult rats improved CST sprouting and sensorimotor 
recovery16. We had originally expected that AAV1 would be trafficked from muscle to the spinal 
cord retrogradely in axons17 and that enhanced secretion of NT3 by motor neurons would lead to 
sprouting of the spared CST9, 18, 19 and sensorimotor recovery. However, although NT3 protein 
was overexpressed in injected muscles, to our surprise we found little evidence for expression of 
the human NT3 transgene in the spinal cord or cervical DRGs14, 16 using this modest dose of AAV. 
This serendipitous result led us to reject our original assumption that sensorimotor recovery 
required expression of the human NT3 transgene in the spinal cord and to wonder whether 
intramuscular infusion of NT3 protein would suffice.  
Accordingly, here, we tested the hypothesis that infusion of NT3 protein (14 kDa) into impaired 
forelimb muscles would improve sensorimotor recovery after stroke (i.e., bypassing the need for 
gene therapy and spinal surgery). This is plausible because others have shown that a signal from 
muscle spindles can improve neuroplasticity of descending pathways and can enhance recovery 
after spinal cord lateral hemisection20. Notably, NT3 protein is synthesised by muscle spindles21 
and NT3 can be transported from muscle to sensory ganglia and spinal motor neurons in nerves6, 
14, 16 as well as to the CNS and PNS via the bloodstream22-24. Importantly, NT3 protein has 
excellent translational potential: Phase I and II clinical trials have shown that repeated, systemic, 
high doses of NT3 protein are well-tolerated, safe and effective in more than 200 humans with 
sensory and motor neuropathy (Charcot-Marie-Tooth Type 1A)25 or constipation including in 
people with spinal cord injury25, 26. These studies pave the way for NT3 as a therapy for stroke in 
humans. We now show in a blinded, randomized preclinical trial that treatment of impaired upper 
arm muscles with human NT3 protein reverses sensory and motor disability in rats when treatment 
is initiated in a clinically-feasible timeframe (24 hours after stroke). 
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Methods  
Full methodological details are available on-line27. 
Experimental design 
All surgical procedures and behavioural testing were performed using a randomised block design 
with experimenters and principal investigator blinded to treatment groups by a third party27. All 
procedures were in accordance with the Animals (Scientific Procedures) Act of 1986. All protocols 
involving animals received prior approval by the King’s College London Animal Welfare Ethical 
Review Board and were authorised by the UK Home Office Project Licence number 70/7865 held 
by Dr Moon. 
Stroke or sham lesions 
60 Lister Hooded outbred female rats (~4 months, 200-300g, Charles River) received focal 
ischemic stroke in the sensorimotor cortex representing the dominant forelimb (Fig. 1), defined 
by the cylinder test, as described for elderly rats16 (Fig. 1A,B) with minor modifications as 
described in detail elsewhere27. Briefly, anesthetised animals were transferred to a stereotaxic 
frame where a midline incision was made, the cortex was then exposed via craniotomy using the 
following co-ordinates [defined as anterioposterior (AP), mediolateral (ML)]: AP 4 mm to − 2 mm, 
ML 2 mm to 4 mm, relative to bregma. Endothelin-1 (ET-1, 400 pmol/µL in sterile saline; 
CalBioChem) was applied using a glass micropipette attached to a Hamilton syringe. 1 µl of ET-
1 to was applied to the overlying dura to reduce bleeding, and immediately thereafter, the dura 
mater was incised and reflected. Four 1 μl volumes of ET-1 were administered topically and four 
1 µl volumes were microinjected intracortically (at a depth of 1 mm from the brain surface) at the 
following co-ordinates (from bregma and midline, respectively): 1) AP +3.5 mm, ML 2.8 mm; 2) 
AP +2.0 mm, ML 2.8 mm; 3) AP +0.5 mm, ML 2.8 mm; 4) AP –1.0 mm, ML 2.8 mm. Temperature 
was maintained using a rectal probe connected to a homeothermic blanket (Harvard Apparatus, 
USA) placed under the animal which maintained rectal temperature at 36 ± 1°C. Prior to suturing, 
the animal was left undisturbed for 5 minutes. The skull fragment was then replaced and sealed 
using bone wax (Covidien, UK). Five sham-operated rats received all procedures excluding 
craniotomy. All rats survived this surgery. Animals were given buprenorphine (0.01 mg/kg, 
subcutaneously).  
Structural and functional MRI 
Structural MRI images were obtained prior to stroke, 24 hours after stroke and at one and eight 
weeks after stroke as described with full details elsewhere16, 27. fMRI was performed prior to stroke 
and at one and eight weeks after stroke during non-noxious stimulation of the affected wrist as 
described fully elsewhere27 in a subset of rats that did not receive intracortical injections of BDA 
tracer (n=10/group). Two animals died following alpha chloralose anaesthesia due to breathing 
difficulties in recovery. 
NT3 or vehicle treatment 
Twenty-four hours after stroke (immediately after MRI), rats were randomised to treatment using 
NT3 or vehicle, infused into affected triceps brachii muscles for one month via thin, flexible 
implanted catheters and subcutaneous osmotic minipumps (2ML2, Alzet; 5 µl/hour flow rate, 2 ml 
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reservoir) compatible with MRI27. Full technical details have been provided elsewhere27. 
Treatments were vehicle (0.9% saline containing 0.1% bovine serum albumin; Sigma; A3059; 
9048-46-8) or vehicle containing recombinant human NT3 (100 µg/ml; gift of Genentech Inc., 
USA). Pumps were replaced after two weeks and removed after four weeks. Skin was sutured 
and analgesic administered as above. All rats survived this surgery. Pilot experiments showed 
that the pump flow rate (5 µl/hour) was sufficient to deliver substances (0.9% saline containing 
1% Fast Green, Sigma) to the entire volume of the triceps muscles. The identity of this preparation 
of NT3 was confirmed to consist of the ~14 kDa monomer and ~28 kDa dimer by SDS-PAGE and 
liquid chromatography-mass spectrometry27. The NT3 dose (12 µg per 24 hours) was selected 
based on previous experiments28.  
Enzyme Linked Immunosorbent Assay (ELISAs) 
A random subset of rats (n=5/group) were anesthetised (4 weeks following stroke, before pumps 
were removed) and triceps brachii and C7 spinal cord were rapidly dissected and snap frozen in 
liquid nitrogen prior to storage at -80°C. Tissue was homogenised in ice cold lysis buffer 
containing 137 mM NaCl, 20 mM Tris-HCl  (pH 8.0), 1% NP40, 10% glycerol, 1 mM 
phenylmethanesulfonylfluoride, 10 μg/ml aprotinin, 1 μg/ml leupeptin and 0.5 mM sodium 
vanadate, using 10 µl buffer per mg of tissue. Protein content was measured and NT3 ELISA was 
carried out according to manufacturer’s instructions (Emax, Promega). Full details have been 
given elsewhere27. 
Behavioural testing 
Rats were handled and trained for three weeks on the horizontal ladder before the study began. 
Preoperative baseline scores for the horizontal ladder, the vertical cylinder and the grip strength 
test were collected one week before surgery.   
Assessment of somatosensory responsiveness: The “adhesive patch” test was used to 
measure 1) the time taken to contact stimuli on the wrists, 2) the time taken to remove stimuli 
from the wrists, and 3) the magnitude of lack of responsiveness to stimuli on the affected wrist  as 
previously described16, 27. To determine whether the rats preferentially removed a sticker from 
their less-affected wrist before their more-affected wrist, the order and side of label removal was 
recorded. This was repeated four times per session until a >75% preference had been found; if 
this was not the case a fifth trial was conducted. The magnitude of asymmetry was established 
using the seven levels of stimulus pairs on both wrists as previously described (Figure 2A). From 
trial to trial, the size of the stimulus was progressively increased on the affected wrist and 
decreased on the less affected wrist by an equal amount (14.1 mm2), until the rat removed the 
stimulus on the affected wrist first (reversal of original bias). The higher the score, the greater the 
degree of somatosensory impairment. 
Walking: To assess impairments in forelimb and hindlimb function after stroke, rats were 
videotaped as they walked along a horizontal ladder 16, 27. Rats were videotaped crossing a 
horizontal ladder (1 m) with irregularly spaced rungs weekly, 3 times per session. Any slight paw 
slips, deep paw slips and complete misses were scored as an error. The mean number of errors 
per step was calculated for each limb for each week.  
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Assessment of forelimb use during rearing: The cylinder test was used to assess asymmetries 
in forelimb use for postural support during rearing within a transparent 20 cm diameter and 30 cm 
high cylinder16, 27. An angled mirror was placed behind the cylinder to allow movements to be 
recorded when the animal turned away from the camera. During exploration, rats rear against the 
vertical surface of the cylinder. The first forelimb to touch the wall was scored as an independent 
placement for that forelimb. Subsequent placement of the other forelimb against the wall to 
maintain balance was scored as “both.” If both forelimbs were simultaneously placed against the 
wall during rearing this was scored as “both.” A lateral movement along the wall using both 
forelimbs alternately was also scored as “both.” Scores were obtained from a total number of 10 
full rears to control for differences in rearing between animals. Once scores had been acquired, 
forelimb asymmetry was calculated using the formula: 100 × (ipsilateral forelimb use + 1/2 bilateral 
forelimb use)/total forelimb use observations. 
Anatomical tracing 
To visualize uninjured CST axons, six weeks after stroke, 10% biotinylated dextran amine (BDA) 
in PBS (pH 7.4) was microinjected unilaterally into the uninjured sensorimotor cortex as described 
previously 16, 27. Briefly, animals were placed in a stereotaxic frame and six burr holes were made 
into the skull at the following coordinates (defined as anterioposterior (AP), mediolateral (ML): 1) 
AP: +1 mm, ML: 1.5 mm; 2) AP: +0.5 mm, ML: 2.5 mm; 3) AP: +1.5 mm, ML: 2.5 mm; 4) AP: +0.5 
mm, ML: 3.5 mm; 5) AP: +2.0 mm, ML: 3.5 mm; 6) AP: - 0.5 mm, ML: 3.5 mm, relative to bregma. 
At each site, 0.5 μl injections of BDA (10% in PBS) were delivered using a glass micropipette 
attached to a Hamilton syringe inserted 2 mm from the skull surface and delivered at a rate of 
0.25 μl/min. Animals were left for 2 weeks before being perfused. Tract tracing was not performed 
in rats that were to undergo fMRI or neurophysiology. 
Neurophysiology 
We recorded from the ulnar nerve on the affected side and stimulated, in the pyramids, the CST 
corresponding to the affected or less-affected hemisphere, as described previously27. At the end 
of the study, 18 rats (6 rats per group) were anaesthetised with an intraperitoneal injection of 
1.25g/kg urethane (Sigma-Aldrich). The rat was kept at 37°C with a homeothermic blanket system 
and rectal thermometer probe. Tracheotomy was performed and a tracheal cannula inserted. The 
pyramids were then exposed ventrally by blunt dissection and removal of a small area of bone. 
The brachial plexus of the affected forelimb was exposed from a ventral approach by dissecting 
the pectoralis major. The ulnar and median nerves were dissected free from surrounding 
connective tissue and cut distally (to prevent twitches of target muscles). Skin flaps from the 
incision formed a pool, which was filled with paraffin oil. The proximal segment of the ulnar nerve 
was mounted on a pair of silver wire hook electrodes (with >1 cm separation). The concentric 
bipolar stimulation electrode (FHC CBBPC75) was located 1 mm lateral to the midline and gently 
lowered through the pyramid up to a maximum depth of 1.5 mm while stimulating at 300 μA (four 
pulses, square wave pulse width 100 µs; frequency 500 Hz). At the electrode location providing 
maximal ulnar nerve response, stimuli of increasing intensity were applied in the range of 50 µA 
to 400 µA, in 50 µA increments. Five sweeps were captured at each stimulus intensity. The signal 
was rectified and the area under the curve was measured between 17 and 45 ms. Data were 
Page 7 
 
analysed using two-way repeated measures ANOVA. Graphs show mean and standard error of 
the mean for the area under the curve for stimuli given at 400 µA. 
Histology 
Eight weeks after stroke surgery and two weeks after injection of BDA, rats were terminally 
anesthetized with sodium pentobarbital (80 mg/kg; i.p.) and perfused with PBS for 5 minutes, 
followed by 500 ml of 4% paraformaldehyde in PBS for 15 minutes. The brain, C6-C8 spinal cord, 
C7 and C8 DRGs and both arms were carefully dissected and stored in 4% paraformaldehyde in 
PBS for 2 hours and then transferred to 30% sucrose in PBS and stored at 2-5°C.  Spinal cord 
segments C1 and C7 was embedded in OCT and 40 μm transverse slices were cut using a 
freezing stage microtome. Ten series of sections were collected.   
Series of 40 μm-thick transverse sections of fixed spinal cord were immunolabelled as previously 
described 16, 27. Primary antibodies (overnight) were: rabbit anti-PKCγ (1:500, sc-211, Santa Cruz 
Biotechnology); rabbit anti-serotonin (1:6000, #20080, Immunostar).  Secondary antibodies (3 h) 
were: goat anti-rabbit IgG Alexa 488 (1:1000, Invitrogen) with DAPI (1:50,000, Sigma).  
BDA staining was performed as described before 16, 27. CST axons were counted that crossed the 
midline, at two more lateral planes and at an oblique plane (Figure 3A) on the affected side at C7 
and C1. For each rat, we estimated the number of CST axons per cord segment by calculating 
the average number of CST axons per section and then multiplying by a scaling factor (number 
of sections per segment).  
The total length of serotonergic processes was measured using a method14 that is well suited for 
quantification of dense terminal arbors. Processes were identified using the “adjust threshold” 
function in ImageJ and fiber lengths were measured in 4 areas: the dorsal horn, intermediate grey 
and ventral horn (Fig. 4B) in 3 sections per rat. We calculated the ratio of the sides ipsilateral and 
contralateral to NT3 treatment for the 3 areas separately. 
Immunofluorescence was visualized under a Zeiss Imager.Z1 microscope or a confocal Zeiss 
LSM 700 laser scanning microscope. Photographs were taken using the Axio Cam and AxioVision 
LE Rel. 4.2 or the LSM Image Browser software for image analysis.  
Radiolabelling of NT3 
NT3 protein was radiolabelled with 50 µCi (1.85 MBq) N-succinimidyl [2,3-3H]propionate (3H-NSP) 
and separated from unbound 3H-NSP using an ÄKTAprime purification system using a 
modification of a previous method29. 50 µg [3H]NT3 or [3H]albumin was injected intravenously as 
a 300 µL bolus into 95 adult C57Bl/6 mice (7-8 weeks old). This method had been optimised for 
mice. After 3, 15, 20, 30, 40, 60 or 90 min, brain, spinal cord and serum were taken for scintillation 
counting. The rate of influx (Ki) was calculated from the Patlak plot30 of VD for [3H]NT3 and 
[3H]albumin against the plasma area under the curve.  
The same treatment was repeated for mice 24 h after stroke, with an incubation period of 40 mins 
(n=6). 0.074 MBq of 14C Sucrose (vascular marker) was injected towards the end of the incubation 
and the brain tissue was taken for capillary depletion analysis. Brain tissue was homogenized in 
physiological buffer (30 µl per mg of tissue) and 26% dextran (40 µl per mg of tissue) as described 
previously31. The homogenate was subjected to density gradient centrifugation (5,400 × g for 15 
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min at 4°C) to give an endothelial cell-enriched pellet and a fraction containing the brain 
parenchyma and interstitial fluid. The samples were solubilized and counted as described above. 
Distribution volume, VD, was calculated. The values were corrected for 14C Sucrose. Data was 
analysed for capillary fraction, parenchymal fraction and whole brain using one-way ANOVA and 
Bonferroni t-tests. 
Statistics 
A set of a priori sample size calculations were performed and reported previously for this 
endothelin-1 model and for four behavioural tests (Montoya staircase test, adhesive patch test, 
cylinder test, horizontal ladder) (see Methods and Table 1 in 32). G⁎Power 3.1 was used to 
estimate the effect size of the difference between the stroke and sham groups for each 
behavioural test using the post hoc algorithm for F tests (Repeated measures, between factors). 
Next, G⁎Power was used33 to estimate the minimum sample sizes that would be required in 
experiments (using two groups) to identify treatment effects of three different magnitudes (25% 
recovery, 50% recovery, 75% recovery) using the a priori algorithm for F tests (Repeated 
measures, between factors) using the following parameters; type I error threshold (α)≤0.05 and 
power (1-β)≥0.80. The “correlation between repeated measures” parameter was derived by 
calculating the mean of the Pearson's product-moment correlation coefficients for each of all 
possible (six) pairs of (four) time points in that study32. In the present study, we chose n=30 for 
the NT3 and vehicle groups in order to increase our chances of detecting small improvements in 
sensorimotor function based on these a priori power calculations. We knew from previous work 
using NT3 what typical effect sizes could be expected in this model16. 
 
Statistical analyses were conducted using SPSS (version 18.0). Graphs show means ± SEMs 
and ‘n’ denotes number of rats or mice. Asterisks (*, **, ***) indicate p≤0.05, p≤0.01 and p≤0.001, 
respectively. Threshold for significance was 0.05. Corticospinal tract sprouting data were 
analysed using one way ANOVA per plane and unpaired t-tests. Serotonergic fibre lengths were 
analysed by region using one-way ANOVA and Bonferroni post hoc tests. Other histology and 
molecular biology data were assessed using Kruskal-Wallis and Mann-Whitney tests. Behavioural 
data were analysed using linear models and Restricted Maximum Likelihood estimation to 
accommodate data from rats with occasional missing values (using SPSS MIXED with Fisher’s 
Least Squares Difference post hoc tests as described previously34). Baseline scores were used 
as covariates. Post hoc p-values were only reported when the preceding global (protected) test 
(e.g., factorial linear models, one-way ANOVAs or Kruskal-Wallis tests) was significant for the 
main effect or any interaction term (p<0.05). For transparency, post hoc p-values are stated 
exactly (or when small, as p<0.001, for example). Degrees of freedom are reported to nearest 
integer. Normality was assessed using histograms. Tests were two-tailed.  
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Results 
MRI confirmed equivalent infarct volumes between stroke groups 
MRI confirmed that infarcts included the forelimb and hindlimb areas in sensorimotor cortex (Fig 
1C). There was no difference in the mean infarct volume between stroke groups at 24 h (Fig. 1D) 
or one or eight weeks after stroke. Loss of CST axons was assessed at 8 weeks in the upper 
cervical spinal cord using protein kinase C gamma (PKCγ) immunofluorescence35, 36 (Fig. 1E). 
Stroke caused a 24% loss of CST axons in the dorsal columns of the upper cervical spinal cord 
relative to shams (Fig. 1F) with no difference between vehicle and NT3 treated rats. Together, 
the MRI and PKCγ histology data indicate that there were no confounding pre-treatment 
differences in mean infarct volumes and that NT3 did not act as a neuroprotective agent, as 
expected, based on our previous results16 and given that treatment was initiated after the majority 
of cell death would have occurred.  
 
Delayed NT3 improved forelimb sensory and motor function after stroke 
An adhesive patch was attached to each wrist of the rat and the order of their removal was noted. 
From trial to trial, the size of the patch was progressively increased on the affected wrist and 
decreased on the less affected wrist by an equal amount (Fig. 2A), until the rat removed the patch 
on the affected wrist first. A high score (e.g. 6) denotes a deficit (i.e., that a rat preferentially 
removed the smaller stimulus from their less-affected wrist). The two stroke groups exhibited a 
similar lack of responsiveness to stimuli on their affected wrist after one week (Fig. 2B) and NT3 
enhanced recovery compared to vehicle. Thus, NT3 improved responsiveness to tactile stimuli 
after stroke.  
Walking was assessed using a horizontal ladder with irregularly spaced rungs (Fig. 2C). Accurate 
paw placement during crossing requires proprioceptive feedback from muscle spindles20. After 
one week, the two stroke groups made a similar number of errors with their affected forelimb (Fig. 
2D). NT3 caused a progressive recovery after stroke relative to vehicle treated animals. This is 
consistent with previous experiments from our lab14, 16. Stroke also caused modest long-lasting 
hindlimb deficits on the ladder; as expected, infusion of NT3 into the forelimb triceps brachii did 
not improve hindlimb movements (data in archive27). 
Neurotrophin-3 also restored the use of the affected forelimb for lateral support when rats reared 
in a vertical cylinder (Fig. 2E). After stroke and vehicle treatment, rats used their affected forelimb 
less often than shams. NT3-treated rats showed more frequent use of the affected forelimb 
relative to vehicle-treated rats (Fig. 2F). Stroke caused transient weakness in forelimb grip 
strength in both groups but infusion of NT3 into triceps brachii did not modify grip strength (data 
in archive27).  
In summary, infusion of NT3 protein into the triceps brachii induced recovery on both sensory and 
motor tasks that require control of muscles by pathways including CSTs, serotonergic raphespinal 
pathways and proprioceptive circuits. Accordingly, we hypothesised that NT3 would induce 
neuroplasticity in multiple pathways. 
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NT3 induced neuroplasticity in multiple spinal locomotor pathways 
We examined neuroplasticity in the C7 cervical spinal cord because we knew from experiments 
using adult and elderly rats that the less-affected CST sprouts at this level after injection of AAV-
NT3 into muscles including triceps brachii 16. Indeed, anterograde tracing from the less-affected 
sensorimotor cortex (Fig. 1B) revealed that NT3 treatment increased sprouting of the CST in the 
C7 spinal cord (Fig. 3A,B) across the midline and into the affected side at two more lateral planes, 
and also from the ventral CST.  
We assessed neural output in the ulnar nerve on the affected side, whose motor neurons are also 
found in C7 (range: C4 to C8) and which supply muscles in the forearm including the hand37. To 
do this, we recorded responses during electrical stimulation of either the less-affected CST (Fig. 
3C) or the partially-ablated CST (Fig. 3f) in the medullary pyramids. NT3 treatment led to 
enhanced responses in the ulnar nerve during stimulation of the less-affected (Fig. 3 D, E) and 
more-affected (Fig. 3G, H) pathways. This result is consistent with the sprouting of traced CST 
axons (Fig. 3A,B) and indicates that CST axons from both the stroke hemisphere and the 
contralesional hemisphere strengthened connectivity to the cord on the treated side, most likely 
on pre-motor interneurons that lie between CST axons and motoneurons. We also found that NT3 
treatment caused serotonergic axons to sprout in the ventral C7 spinal cord (Fig. 4A-D). 
Anatomical and functional plasticity of corticospinal and serotonergic pathways is consistent with 
their expression of receptors for NT3 2, 3. 
We conclude that NT3 caused neuroplasticity in multiple descending locomotor pathways. These 
data are consistent with our findings14, 16 that intramuscular AAV-NT3 can, directly or indirectly, 
enhance spinal plasticity after stroke. Next, we assessed the biodistribution of NT3 after 
peripheral administration. 
 
Neurotrophin-3 enters the PNS and CNS after peripheral administration  
ELISA revealed an increase in total NT3 protein levels in the triceps brachii on the treated side 
(Fig. 5A) and, surprisingly, on the untreated side (likely due to NT3 secreted into the bloodstream 
and taken up by endothelial cells; see below). We were not able to detect any small increases in 
exogenous human NT3 against the background of endogenous rat NT3 in the C7 spinal cord 
(data in archive27) because the amino acid sequences for mature human and rat NT3 are 
identical38. Accordingly, we next used a more sensitive method for measuring trafficking of 
exogenous NT3 across the blood-CNS barrier. 
Radiolabelled NT3 was injected intravenously into adult mice. Radiolabelled albumin was used 
as a control because it does not enter the CNS efficiently from the bloodstream. After 3, 15, 20, 
30, 40, 60 or 90 minutes, brain, spinal cord and serum were taken for scintillation counting. 
[3H]NT3 progressively accumulated in the intact brain (Fig. 5B) and cervical spinal cord (Fig. 5C). 
In plasma, the half-life of NT3 was short (Fig. 5D). Our data is consistent with that from others22-
24: for example, after injection of radiolabelled NT3 into the brachial vein (which provides drainage 
from the triceps brachii), NT3 accumulates in the cortex, striatum, brainstem, cerebellum, spinal 
cord and sciatic nerve, although the majority of NT3 is cleared rapidly from the bloodstream22, 23. 
Moreover, the blood-nerve barrier in DRGs is fenestrated and permeable to proteins like NT339.  
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Next, [3H]NT3 or [3H]albumin was injected intravenously into adult mice 24 hours after cortical 
ischemia. Forty minutes later, tissues were taken for scintillation counting. Again, [3H]NT3 
accumulated in the brain (Fig 5E). To confirm entry of [3H]NT3 into brain parenchyma beyond 
endothelial cells, capillaries were depleted by gradient centrifugation to yield a fraction containing 
brain parenchyma and an endothelial cell-enriched pellet. [3H]NT3 entered parenchyma (depleted 
of endothelial cells) at a level above that seen for [3H]albumin (Fig. 5F). Transport of NT3 into the 
CNS is apparently a receptor-mediated process12,13,44.  
We conclude that neuroplasticity occurred in multiple locomotor pathways because peripherally-
administered NT3 bound to receptors in the PNS and CNS. 
BOLD signal in perilesional somatosensory cortex evoked by stimulation of the affected 
wrist recovers with time after stroke and is not further enhanced by NT3 
To explore the mechanism whereby NT3 improved responsiveness to stimuli attached to the 
affected wrist (Fig. 2B), we performed BOLD-fMRI during low intensity (non-noxious) electrical 
stimulation of the affected wrist (Fig. 6). As expected, prior to stroke, stimulation of the wrist 
resulted in a higher probability of activation of the opposite somatosensory cortex (Fig. 6A). One 
week after stroke, somatosensory cortex was not active when the affected paw was stimulated in 
either vehicle or NT3 treated rats (p-values>0.05, Fig. 6B). fMRI performed eight weeks after 
stroke revealed a trend towards perilesional re-activation of somatosensory cortex in both vehicle 
and NT3 treated groups (p-values<0.05, Fig. 6C). However, these probabilities of re-activation 
were not big enough to survive correction for testing of multiple voxels (threshold=0.01).  
A longitudinal analysis showed that at 8 weeks, there was some evidence that rats treated with 
NT3 showed increased probability of activation of perilesional cortex (Fig. 6D, p-values<0.05) and 
showed decreased probability of activation of cortex in the less-affected hemisphere (p-
values<0.05) relative to vehicle-treated stroke rats. However, these apparent differences did not 
survive correction for testing of multiple voxels (threshold=0.01). We conclude that both groups 
showed partial, spontaneous restoration of more-normal patterns of somatosensory cortex 
activation40 but, conservatively, that NT3 did not further increase probability of activation of any 
supraspinal areas. These conclusions are consistent with previous fMRI data from our 
laboratory16; we propose that the additional recovery of somatosensory function after NT3 
treatment (Fig. 2B) is due to changes in the spinal cord rather than in supraspinal areas.  
Neurotrophin-3 did not cause detectable hypersensitivity 
Finally, we also found no evidence that stroke or NT3 caused hypersensitivity in the forepaw, 
assessed by application of ice-cold acetone (Fig. 7). This is consistent with our previous work 
showing a lack of mechanical hyperalgesia after NT3 treatment14 and with the lack of TrkC on 
adult nociceptors5 and with the human clinical trial data showing that subcutaneous treatment with 
NT3 was safe and well-tolerated25, 26. 
  
  
Page 12 
 
Discussion 
Intramuscular infusion of NT3 protein, initiated 24 hours after stroke, caused changes in multiple 
locomotor circuits, and promoted a progressive recovery of sensorimotor function in rats. The fact 
that NT3 can reverse disability when treatment is initiated 24 hours after stroke is exciting because 
most stroke victims are diagnosed within this time frame. NT3 could potentially be used to treat 
many survivors. 
NT3 has good clinical potential. Firstly, Phase II clinical trials show that doses up to 150 µg/kg/day 
are well tolerated and safe in healthy humans and in humans with other conditions25, 26. We used 
a threefold lower dose (48 µg/kg/day) in this study: in future experiments we will optimize the dose 
and duration of treatment because it is possible that a higher dose of NT3 would promote 
additional recovery. Secondly, there is conservation from rodents to humans in the expression of 
receptors for NT3 in the locomotor system2, 3. Thirdly, in none of our rodent experiments has NT3 
treatment caused any detectable hypersensitivity, spasticity or muscle weakness; rather, after 
bilateral CST injury in rats, intramuscular delivery of AAV-preproNT3 reduced spasms, slightly 
improved grip strength and showed a trend towards reducing mechanical hyperalgesia14. 
We used fMRI during electrical stimulation of the wrist to explore recovery of somatosensory 
responsiveness to adhesive patches attached to the wrist. We confirmed work by others that 
spontaneous recovery correlated well with more-normal patterns of increased BOLD signal 
surrounding the infarct40, 41 but, as before16, we did not find strong evidence that NT3 further 
increased peri-lesional (or other) activation. Accordingly, we propose a different hypothesis: that 
NT3 increased somatosensory recovery27 by inducing neuroplasticity in spinal circuits involving 
cutaneous afferents. Indeed, using a different animal model, we have previously shown that NT3 
normalises output from spinal circuits following stimulation of low threshold afferents from the 
treated wrist14 (which would activate cutaneous afferents as well as proprioceptive afferents, both 
of which express receptors for NT35). However, in those experiments we measured output in 
motor axons rather than sensory output so in the future we might examine whether NT3 modulates 
gating of somatosensory inputs from the wrist42 after stroke.  
With regard to corticospinal neuroplasticity, we have shown twice previously (in adult and elderly 
rats) that the less-affected CST sprouts across the cervical midline into the affected hemicord 
after injection of AAV-NT3 into affected forelimb muscles16. Others have shown that intrathecal 
infusion of NT3 induces sprouting of the CSTs13 and that injection of vectors encoding NT3 into 
muscles8 or nerve9 induces CST sprouting after spinal cord injury. Here, our anatomical tracing 
confirmed that the less-affected CST sprouted after infusion of NT3 protein into triceps and in 
future we will trace both CSTs. This is because, in the present study, neurophysiology revealed 
that both CSTs underwent plasticity to the affected side after unilateral infusion of NT3 protein.  
We propose that spared CST axons sprouted after NT3 entered the CNS from the systemic 
circulation. This is consistent with data from us and others showing that radiolabelled NT3 entered 
the brain and spinal cord after intravenous injection22-24. Moreover, it has been shown that 
endogenous muscle spindle-derived cues induce sprouting of descending pathways after spinal 
cord injury in adult mice20; given that muscle spindles make NT3 endogenously21, it is plausible 
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that infusion of supplementary NT3 to muscle might directly enhance CST sprouting after stroke 
via TrkC receptors on corticospinal axons3, 43.  
It is possible, additionally, that NT3 was trafficked from forelimb muscles in axons to motor 
neurons and/or to DRG neurons where it induced expression of a molecule that was secreted and 
induced CST sprouting. NT3 is certainly trafficked to ipsilateral motor neurons and DRG after 
intramuscular delivery4, 6, 14, 16, 44. Diffusion within neuropil is inefficient45 but spinal motor neuron 
dendritic arbors can be very large (some even extend across the midline46) and these might widely 
distribute a cue for supraspinal axonal plasticity (e.g., across the midline). In another project, to 
seek DRG-derived factors, we have performed RNAseq of cervical DRG after injection of AAV-
NT3 into forelimb flexors14, 47. In the future we will also seek motor neuron-derived cues that are 
regulated by NT3.  
Unilateral stroke often causes bilateral impairments in humans and other mammals 48. In principle, 
intramuscular infusion of NT3 into an affected muscle might (after distribution of NT3 in the 
bloodstream) enhance sprouting of CST axons to the less-affected side (as well as the affected 
side) thereby increasing output to forelimb motor nerves in the less-affected limb. However, 
impairments on the less-affected side are modest and transient in rats with this model of stroke 
27, 32 and so any neuroplasticity might be difficult to detect. It is also notable that infusion of NT3 
into a proximal forelimb extensor improved the accuracy of use of the affected forelimb when 
walking on a horizontal ladder but did not improve the accuracy of the affected hindlimb (see 27); 
this implies that circulating NT3 is not sufficient to improve hindlimb movements. Moreover, 
infusion of NT3 protein into triceps brachii did not improve forelimb grip strength27: however, the 
grip strength task probably depends more on strength in hand and digit flexor muscles (into which 
NT3 was not infused) than on triceps brachii (elbow extensors). Indeed, injection of AAV-NT3 into 
proximal and distal flexor forelimb muscles does modestly improve grip strength14. Taken 
together, these results indicate that it may be strategic to target NT3 to multiple muscles. 
Finally, it is encouraging, from a translational perspective, that the recovery continues even after 
infusion of NT3 is discontinued at four weeks. We propose that the four-week long NT3 treatment 
induces changes in target cells that persist (e.g., due to sustained modifications in gene 
expression). Indeed, longer treatment with NT3 induces different intracellular signalling events in 
sensory axons than does brief treatment, thereby enhancing terminal branching49. We are 
currently seeking factors that are persistently increased in target neurons after NT3 treatment is 
discontinued. Additionally, it may be that NT3 induces sprouting of CST axons that (after 
cessation of treatment) is followed by selection of synapses (e.g., strengthening or pruning) by a 
mechanism that is independent of NT3. For example, it is known that corticomotoneuronal axon 
synapses are pruned by repulsive PlexinA1-Sema6D interactions50. To dissect the mechanisms 
whereby NT3 promotes neuroplasticity and recovery after peripheral delivery, we have set up a 
mouse model of stroke. 
In summary, treatment of impaired arm muscles with NT3 (initiated in a clinically-feasible time-
frame) induces spinal neuroplasticity, improves walking and reverses a tactile sensory 
impairment. Other experimental therapies that can be delivered with a delay after stroke includes 
antibodies against Nogo-A which also induce neuroplasticity of cortical efferents51-53. Given the 
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importance of the CST for spontaneous recovery after stroke54, these novel strategies offer 
encouraging prospects for enhancing neural repair. 
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FIGURE 1: Focal stroke caused unilateral infarction in sensorimotor cortex, resulting in a 
loss of corticospinal axons. (A, B) Rats received sham surgery (n=5) or unilateral cortical stroke 
and 24 hours later infusion of NT3 (n=30) or vehicle (n=30) into the affected triceps brachii was 
initiated for one month. Six weeks after stroke, anterograde tracer was injected into the 
contralesional sensorimotor cortex. Rats underwent 8 weeks of behavioural testing. Structural 
MRI was conducted on all rats at 24 hours, 1 week and 8 weeks after stroke and fMRI was 
conducted in a subset of rats at baseline, week 1 and week 8. Electrophysiology was performed 
in the subset of rats which did not receive BDA tracing. All surgeries, treatments and behavioural 
testing were performed using a randomized block design and the study was completed blinded to 
treatment allocation. (C) T2 MRI scans 24 hours after stroke, immediately prior to treatment, 
showing infarct in coronal sections rostral (mm) to bregma. (D) There were no differences 
between stroke groups in mean lesion volume at 24 hours (Mann-Whitney p-value=0.86). (E) 
Photomicrographs showing loss of CST axons in the upper cervical dorsal columns 8 weeks after 
stroke (right) relative to sham surgery (left), visualised using PKCγ immunofluorescence. (F) 
Stroke caused a significant loss of CST axons relative to shams (Kruskal-Wallis χ2=12.0, p=0.002; 
Mann-Whitney p-values<0.001) with no differences between vehicle and NT3 treated rats (Mann-
Whitney p=0.96). Representative images of one stroke and one sham animal are shown. Panel 
B modified from reference 16 with permission. 
 
FIGURE 2: Delayed NT3 treatment improved responsiveness to somatosensory 
stimulation, improved walking and partially restored use of the affected forelimb for lateral 
support during rearing.  (A-C) Somatosensory deficits were assessed using A) pairs of adhesive 
patches attached to the rat’s wrists. (B) Treatment with NT3 caused improvement compared to 
vehicle (linear model; F2,126=32.5, p<0.001; post hoc p=0.003): whereas vehicle-treated stroke 
rats showed a deficit relative to sham rats which persisted for eight weeks (linear model; 
F14,263=4.1, p<0.001; post hoc p values<0.02), NT3 caused improvements such that by six weeks 
they had recovered fully relative to shams (post hoc p values>0.4) and to vehicle-treated stroke 
rats (post hoc p values<0.001). There were no differences between NT3 and vehicle treated rats 
at one week (t-test p=0.33). (C) Accuracy of paw placement by the affected forelimb during 
walking was assessed using a horizontal ladder with irregularly spaced runs. (D) One week after 
stroke, NT3 and vehicle treated rats made a similar number of misplaced steps (t-test p=0.78), 
expressed as a percentage of total steps. Importantly, the NT3 group progressively recovered 
compared to the vehicle group (group F2,52=17.0, p<0.001; post hoc p=0.008) and differed from 
the vehicle group from weeks 5 to 8 (group x time F14,355=6.2, p<0.001; post hoc p values<0.005) 
and whereas the vehicle group remained impaired relative to shams from weeks 5 to 8 (p 
values<0.006), from weeks 5 to 8 the NT3 group made no more errors than shams (post hoc 
p-values>0.05). (E) The vertical cylinder test assessed use of the affected forelimb for lateral 
support during rearing. (F) Stroke caused a reduction in the use of the affected forelimb during 
rearing in a vertical cylinder in both NT3 and vehicle treated rats relative to shams (group 
F2,56=6.1, p=0.004; post hoc p values=0.001 and 0.003, respectively) with no differences between 
stroke groups at one week (p=0.52). NT3 treatment caused a progressive recovery in the use of 
the affected forelimb (group*wave F14,356=1.78, p=0.04) by weeks 7 and 8 relative to vehicle 
treated rats (p values = 0.015 and 0.067, respectively). Sham group n=5, Stroke and NT3 group 
Page 20 
 
n=29, Stroke and vehicle group=28. Sham rats represented by circles with dashed lines, NT3 
stroke rats represented by triangles and solid lines and Vehicle stroke rats represented by 
squares with dotted lines. 
 
FIGURE 3: Delayed neurotrophin-3 treatment caused CST sprouting and increased output 
in forelimb motor nerves during CST stimulation. (A) Corticospinal axons were anterogradely 
traced from the less-affected cortex and were counted at the midline (M), at two more lateral 
planes (D1 and D2) and crossing into grey matter from the ipsilateral, ventral tract (Ipsi). (B) NT3 
treatment caused an increase in the number of axons crossing at the midline (F2,28=6.1, p=0.007; 
post hoc p value=0.003), at two lateral planes denoted as D1 (F2,28=20.3, p<0.001, post hoc p 
value<0.001) and D2 (F2,28=13.8,p<0.001, post hoc p value<0.001) and from the ventral CST on 
the treated side (F2,28=5.2, p=0.013, post hoc p value=0.005). n=10/group were used for tract 
tracing. (C-E) The CST from the less-affected hemisphere or (F-H) lesioned hemisphere was 
stimulated in the medullary pyramids (before the decussation) and the motor output was recorded 
from the ulnar nerve on the treated side. (D, G) The majority of spikes were detected between 17 
ms and 45 ms, latencies consistent with polysynaptic transmission, in both vehicle-treated rats 
(top trace in D and G) and NT3 treated rats (bottom trace in D and G) when the less-affected or 
affected CST was stimulated. (E, H) Stimulus intensity was increased incrementally from 50 µA 
to 400 µA and the area under the curve were measured (between 17 and 45 ms) after stimulation 
of the affected or less-affected CST. NT3 treatment caused increased output in the ulnar nerve 
during stimulation of either the affected CST (two-way RM ANOVA intensity*group interaction 
F1,14=7.9, p=0.008, n=6 Vehicle, n=6 NT3) or less affected CST (F2,17=9.8, p=0.01, n=4 Vehicle, 
n=6 NT3). Panels A, C and F modified from reference 16 with permission.  
 
FIGURE 4: NT3 treatment caused plasticity of serotonergic axons in the C7 spinal cord. (A) 
The total length of serotonergic arbors was measured in three regions (DH, dorsal horn; IM, 
intermediate horn; V, ventral horn) on the treated side relative to the opposite hemicord. (B) NT3 
treatment did not increase serotonergic arbor length in the dorsal horn or (C) the intermediate 
zone but (D) did increase serotonergic arbor length in the ventral horn relative to Vehicle (one-
way ANOVA F2,22=3.5, p=0.05; Bonferroni post hoc test p=0.025).   
 
FIGURE 5: Levels of NT3 were increased in triceps brachii, in brain and in spinal cord. (A) 
ELISA revealed that, in NT3-treated rats, there was an increase in NT3 in the infused triceps 
brachii (Mann-Whitney vs. vehicle, p=0.032) as well as in the non-infused triceps brachii (Mann-
Whitney vs. vehicle, p=0.032). n=5 rats/group.  (B) [3H]NT3 entered the brain more abundantly 
than [3H]albumin. T-tests for NT3 vs albumin all significant for times of 3, 15, 20 30, 40, 60 and 
90 minutes (p values from <0.01 to <0.0001 ***) which correspond to “exposure times” up to 450 
minutes. Exposure time is calculated as ∫0tCp(τ)dτ/Cp where Cp is concentration in plasma and τ 
is time in minutes. Graph is a Patlak plot30 showing regression of [3H]NT3 (blue circles) and 
[3H]albumin (grey circles) against exposure time after iv injection (n=2-5 mice/time) in adult mice. 
This corrects for the falling plasma concentration of solute with real time as shown in (D). The 
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Volume of Distribution (VD) of [3H]NT3 or [3H]albumin in brain is calculated as a ratio of counts per 
minute (CPM) in 1 µg of brain and CPM in 1 µl of serum for each time point and plotted against 
exposure time (rather than real time). The rate of influx (Ki) was calculated from the Patlak plot30 
of VD for [3H]NT3 and [3H]albumin against the plasma area under the curve. At 1.310-5 μl/mg/s, 
the unidirectional influx constant for NT3, Ki, is 100 times that of the albumin (1.310-7 μl/mg/s). 
(C) [3H]NT3 entered the cervical spinal cord more abundantly than [3H]albumin. Graph shows real 
time and not exposure time. (D) Plasma half-life of NT3 for the normal adult mouse is ~10 min 
(estimated from 1/normalised serum values). Graph shows real time and not exposure time. (E) 
Twenty-four hours after cortical ischemia, [3H]NT3 entered the brain more abundantly than 
[3H]albumin, measured 40 minutes after iv injection. (F) Twenty-four hours after cortical ischemia, 
levels of [3H]NT3 were higher in parenchyma depleted of endothelial cells than levels of 
[3H]albumin 40 minutes after iv injection (parenchyma  p < 0.01; capillary fraction p < 0.05;  and 
whole brain P < 0.001, two-way ANOVA with Bonferroni post hoc tests). Results were corrected 
for the value of VD for 14C Sucrose. Number of mice per group stated on panels. 
 
FIGURE 6: fMRI during stimulation of the affected wrist revealed increased probability of 
perilesional reactivation in both stroke groups but no additional increase by NT3. The same 
rats were imaged prior to stroke and then one week and eight weeks after stroke and 
intramuscular treatment with either NT3 or vehicle. Scans with obvious imaging artefacts were 
discarded, leaving final group numbers of n=7, 9, 7 and n=9, 8, 4 at weeks 0, 1 and 8 for NT3 and 
vehicle treated groups respectively. Red voxels denote greater probability of activation during 
stimulation (versus stimulation off) whereas blue voxels denote lesser probability of activation 
during stimulation (versus stimulation off). A) Prior to stroke, stimulation of the dominant paw led 
to a strong probability of activation in the opposite somatosensory cortex. B) One week after 
stroke, this activation was abolished by infarction. C) Eight weeks after stroke, there was a slight 
trend towards a small perilesional area of reactivation in both groups. D) There was a slight trend 
towards greater perilesional reactivation in the NT3 group versus the vehicle group at 8 weeks 
(relative to their baselines). However, all these heat maps of group mean activations show t-
values obtained by Statistical Parametric Map analysis without correction for multiple testing 
(p<0.05) and there were no differences between the two groups for any voxels when the threshold 
for significance was corrected for multiple testing (p<0.01; this data is not shown as the heat map 
was black). Red voxels denote greater probability of activation during stimulation for the NT3 
group than for the vehicle group whereas blue voxels denote lesser probability of activation for 
the NT3 group than for the vehicle group. When stimulating the less-affected wrist, there were no 
differences between the two groups for any voxels when the threshold for significance was 
corrected for multiple testing (p<0.01; this data is not shown as the heat map was black).  
 
FIGURE 7: Cold allodynia was caused neither by focal cortical stroke nor by treatment with 
NT3. The acetone test was used to see whether stroke and/or NT3 treatment caused any change 
in cold allodynia pain responses.  The test involves applying a drop of acetone to the A) affected 
or B) less affected forelimb, and then allocating a score between 0 and 9: higher numbers denote 
Page 22 
 
a heightened pain response. There is no evidence of painful behaviour based on this test in either 
forelimb.  RM ANCOVA with Bonferroni post hoc tests. 
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